Literature DB >> 25798259

Peroxisome proliferator-activated receptor-α staining is associated with worse outcome in colorectal liver metastases.

Tony Pang1, Antony Kaufman2, Julian Choi3, Anthony Gill4, Martin Drummond3, Thomas Hugh1, Jaswinder Samra5.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors involved in lipid metabolism and liver response to injury. We hypothesised that differences in the expression of PPARs may reflect differences in the cellular microenvironment of the liver and, consequently, in the behaviour of colorectal liver metastases. Of the 145 patients who underwent hepatectomy for colorectal liver metastases between 1998 and 2007, 103 had adequate tissue for PPAR staining and histological re-evaluation. The histological characteristics evaluated included sinusoidal dilatation, perisinusoidal fibrosis, ballooning and steatosis. PPAR- α and-γ staining was performed and the results were correlated with clinical and survival data. Lobular inflammation and sinusoidal dilatation were the most common histopathological abnormalities. A total of 50% of the patients were PPAR- α-negative and 34% were PPAR- γ-negative. More patients exhibited lobular inflammation in the PPAR- α -positive group (P=0.023) compared to patients with negative PPAR- α staining, as seen on the multivariate analysis. PPAR- γpositivity was associated with oxaliplatin use, surgical margins ≥1 mm and a trend towards a lesser degree of fibrosis. The median follow-up in this cohort of patients was 48 months. Patients with PPAR- α staining had a worse overall survival (median, 36 vs. 79 months, P=0.037) compared to those with no PPAR- α staining. There was no correlation between PPAR- α or-γpositivity and disease-free survival. In conclusion, PPAR- α staining is associated with lobular inflammation and worse overall survival in patients with colorectal liver metastases. The exact mechanism underlying this finding remains unclear and further research into the diagnostic and therapeutic implications is required.

Entities:  

Keywords:  cancer microenvironment; colorectal cancer; liver metastases; peroxisome proliferator-activated receptors

Year:  2014        PMID: 25798259      PMCID: PMC4360864          DOI: 10.3892/mco.2014.482

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  28 in total

1.  Metastatic carcinoma in cirrhotic liver--Statistical survey of autopsies in Japan.

Authors:  K Hamaya; H Hashimoto; Y Maeda
Journal:  Acta Pathol Jpn       Date:  1975-03

Review 2.  Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.

Authors:  James M Cleary; Kenneth T Tanabe; Gregory Y Lauwers; Andrew X Zhu
Journal:  Oncologist       Date:  2009-10-30

3.  State disparities in colorectal cancer mortality patterns in the United States.

Authors:  Deepa Naishadham; Iris Lansdorp-Vogelaar; Rebecca Siegel; Vilma Cokkinides; Ahmedin Jemal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07       Impact factor: 4.254

4.  Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy.

Authors:  Paul Ryan; Sulaiman Nanji; Aaron Pollett; Malcolm Moore; Carol-Anne Moulton; Steven Gallinger; Maha Guindi
Journal:  Am J Surg Pathol       Date:  2010-06       Impact factor: 6.394

5.  Epidemiology and management of liver metastases from colorectal cancer.

Authors:  Sylvain Manfredi; Côme Lepage; Cyril Hatem; Olivier Coatmeur; Jean Faivre; Anne-Marie Bouvier
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

6.  Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.

Authors:  Hiroshi Nakano; Elie Oussoultzoglou; Edoardo Rosso; Selenia Casnedi; Marie-Pierre Chenard-Neu; Patrick Dufour; Philippe Bachellier; Daniel Jaeck
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

7.  Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.

Authors:  N N Mehta; R Ravikumar; C A Coldham; J A C Buckels; S G Hubscher; S R Bramhall; S J Wigmore; A D Mayer; D F Mirza
Journal:  Eur J Surg Oncol       Date:  2007-12-21       Impact factor: 4.424

8.  Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.

Authors:  S Kandutsch; M Klinger; S Hacker; F Wrba; B Gruenberger; T Gruenberger
Journal:  Eur J Surg Oncol       Date:  2008-02-12       Impact factor: 4.424

9.  Peroxisome proliferator-activated receptor-alpha regulates postischemic liver injury.

Authors:  Tomohisa Okaya; Alex B Lentsch
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-11-13       Impact factor: 4.052

10.  Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation.

Authors:  Rinke Stienstra; Stéphane Mandard; David Patsouris; Cathy Maass; Sander Kersten; Michael Müller
Journal:  Endocrinology       Date:  2007-03-08       Impact factor: 4.736

View more
  1 in total

Review 1.  Obesity and colorectal cancer: molecular features of adipose tissue.

Authors:  Javier Martinez-Useros; Jesus Garcia-Foncillas
Journal:  J Transl Med       Date:  2016-01-22       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.